Ergothioneine and the Brain: How a Mushroom Amino Acid — and Your Antacids — May Shape Cognitive Aging
A 1,068-person Dutch cohort study found that 14 blood metabolites—led by ergothioneine, a diet-derived antioxidant—track with cognition in dementia-free middle-aged adults, and that this same metabolic signature predicts who later develops Alzheimer’s. Strikingly, antacid use was linked to lower ergothioneine and worse cognition, with the metabolite statistically explaining about a third of the antacid–cognition link.
The brain’s slow slide toward Alzheimer’s disease begins decades before the first forgotten name. The hard problem has always been reading those early signals while there is still time to act. A large international team—anchored at Erasmus MC in Rotterdam, Helmholtz Munich, and Duke University—has now mapped the blood “metabolome” of brain health in midlife, screening 991 circulating metabolites against cognition and brain MRI in over a thousand dementia-free adults averaging 62 years old.
Fourteen metabolites tracked reliably with general cognition. The standout was ergothioneine, a sulphur-containing amino acid the body cannot make—we get it almost entirely from diet, with mushrooms being the richest source. Higher blood levels meant better cognition, and the same signature that marked sharper minds in midlife also marked who would not be diagnosed with Alzheimer’s years later in an older replication cohort. The mirror-image correlation between the cognition signature and future-AD signature was strong (r = −0.73), which is the paper’s most important validation: these are not random hits, but a coherent metabolic fingerprint of brain trajectory.
The team then asked the question biohackers actually care about: are these metabolites modifiable? They partitioned each metabolite’s variance across genetics, gut microbiome, lifestyle, clinical factors, and medication. The answer leaned heavily toward the changeable. Lifestyle, clinical status, and medication—not genes—dominated, explaining up to 28.6% of variance for some metabolites. Genetics and microbiome were comparatively minor contributors for the brain-relevant set.
The headline-grabbing finding is pharmacological. Antacids—particularly proton-pump inhibitors (PPIs), among the most prescribed drugs on earth—were associated with markedly lower ergothioneine and worse cognition. A mediation analysis estimated that roughly 31.5% of the antacid–cognition association ran through reduced ergothioneine, offering a plausible, testable mechanism for the long-disputed link between PPIs and dementia risk.
The authors are appropriately restrained. This is cross-sectional: blood, brain, and pills were all measured at one visit, so cause and effect cannot be untangled. The PPI–cognition link did not even reach significance in their older replication cohort, and the metabolites did not predict cognitive change over time within the discovery group. What the study delivers is not proof but a high-resolution map—and a short list of candidate levers, ergothioneine chief among them, worth chasing in proper longitudinal and interventional work.
Actionable Insights
The single most actionable signal is ergothioneine, and the magnitude is modest but consistent. Each 1 standard-deviation (SD) increase in blood ergothioneine associated with a 0.122 SD improvement in cognition in the discovery cohort (β = 0.122) and 0.073 SD on replication—small effects in absolute terms (roughly a Pearson r ≈ 0.07–0.12), but ergothioneine was the largest of any metabolite tested and replicated across cohorts. Because it is diet-derived (mushrooms are the dominant source; prior work attributes ~14% of its variance to diet), this is a plausible nutritional lever.
The medication signal is concrete: antacid/PPI users showed ~0.45 SD lower ergothioneine (β = −0.45) and a total antacid–cognition effect of β = −0.235 (~quarter-SD worse cognition), ~31.5% mediated by ergothioneine. Practical read: if you chronically use PPIs without strong indication, this is one more (still-unproven) reason to discuss deprescribing or step-down with a clinician.
Secondary levers reflect known wins: smoking drove the worse-cognition sulfated xenobiotics, and diabetes/BMI/alcohol dominated the MRI-marker metabolites. Net: don’t smoke, manage glycemia, and consider dietary ergothioneine. [Confidence: Medium — associational, small effect sizes.]
Source:
-
Institutions: Erasmus MC University Medical Center (lead/discovery), Rotterdam, The Netherlands; Helmholtz Zentrum München, Germany; Duke University, USA (corresponding authors Kaddurah-Daouk and Kastenmüller); with Leiden University, Oxford, and UC Davis.
-
Cohorts: Rotterdam Study (Netherlands) for discovery + replication; Alzheimer Gut Microbiome Project / ADRC network (USA) for second replication.
-
Journal: Nature Aging
-
Impact Evaluation: The impact score of this journal is 25.0 (JIF, 2025 data, released June 2026), evaluated against a typical high-end range of 0–60+ for top general-science and specialty journals, therefore this is a High (near-Elite specialty)